Targeting CLPTM1L By RNA Interference for Treatment and Prevention of Cancer
AssigneeThe Medical College of Wisconsin, Inc.
InventorsMichael Anthony James, Haris G. Vikis, Ming You
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions for reducing CLPTM1L expression in a cell as well as methods for using such compositions to treat or prevent cancer in a subject. In particular, compositions comprising RNAi-inducing constructs targeted to CLPTM1L and methods of administering such compositions to a subject to treat or prevent a disease or condition associated with CLPTM1L over-expression (e.g., lung cancer) are provided herein.
Claims31
An isolated polynucleotide, the polynucleotide comprising or consisting of 19-29 contiguous nucleotides of SEQ ID NO:1.
An RNAi-inducing construct, the construct comprising or consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9, and SEQ ID NO:15.
Dependencies are inferred from the claim text.